{"groups":[{"description":"Patients with confirmed or suspected primary hyperparathyroidism or complications who are missing age and other baseline data because of changes in data management system","id":"FG000","title":"Primary Hyperparathyroidism - Incomplete Data"},{"description":"Patients with confirmed or suspected primary hyperparathyroidism or complications","id":"FG001","title":"Primary Hyperparathyroidism"},{"description":"Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA\n\n68Ga-Dotatate: 68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.\n\n18F-DOPA: 18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.","id":"FG002","title":"DOTATATE and F-DOPA"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"The tracer F-DOPA did not meet Quality Control Standards"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"634"},{"groupId":"FG001","numSubjects":"900"},{"groupId":"FG002","numSubjects":"19"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"634"},{"groupId":"FG001","numSubjects":"900"},{"groupId":"FG002","numSubjects":"16"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}